Last reviewed · How we verify
Provodine-Iodine Solution
Provodine-Iodine Solution, marketed by the Medical University of South Carolina, is an established antiseptic with a strong presence in the healthcare market. The key composition patent, set to expire in 2028, provides a significant period of exclusivity and competitive advantage. However, the lack of revenue data and primary trial results poses a primary risk, as it may limit the drug's ability to attract investment and maintain market share.
At a glance
| Generic name | Provodine-Iodine Solution |
|---|---|
| Sponsor | Medical University of South Carolina |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- RCT Investigating Pre-cesarean Vaginal Wash of Chlorhexidine vs Povidone-iodine for Patient With Ruptured Amniotic Membrane. (PHASE3)
- The Effect of Povidone-iodine Ophthalmic Surgical Prep Solution on Respiration in Children Undergoing Strabismus Surgery With General Anesthesia. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Provodine-Iodine Solution CI brief — competitive landscape report
- Provodine-Iodine Solution updates RSS · CI watch RSS
- Medical University of South Carolina portfolio CI